Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard ®

H-Guard ® Priming Solution

Invizius Limited (“Invizius”), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce that the first two patients have been treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) with lead product, H-Guard® Priming Solution, in the Company’s first-in-human Phase 1 clinical study.

Continuation of the Study

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved continuation of the study, following the submission of safety and performance data from the first two patients. Up to eight more patients will be recruited to the CRF, the only UK site to participate in the study. The study is being conducted at the NIHR Manchester CRF at the Manchester Royal Infirmary (MRI), part of the Manchester University NHS Foundation Trust, and is led by Professor Sandip Mitra and Co-investigators, Dr Leonard Ebah and Dr Duha Ilyas.

Safety and Tolerability

The study is investigating the safety and tolerability of lead product, H-Guard, in patients undergoing haemodialysis (HD) who are vulnerable to dialysis-induced immune activation. Immune activation occurs when a patient’s blood comes into contact with foreign surfaces in the dialysis circuit, which can result in excessive inflammation, coagulation, vascular and organ damage and other adverse consequences. H-Guard is flushed through the dialysis machine prior to commencing treatment and aims to prevent serious complications by attenuating the patient’s immune response to the dialysis procedure.

Richard Boyd, Chief Executive Officer of Invizius, said:

“The treatment of the first patients with our lead product, H-Guard, is a major milestone for Invizius as we enter clinical development with our first-in-human Phase 1 study at the Manchester Clinical Research Facility. We are pleased to have received MHRA approval to continue the study after a prearranged, two-patient safety and performance review, and we are excited by the potential of H-Guard to improve the treatment paradigm of patients on dialysis.”

Professor Sandip Mitra, Consultant Nephrologist and Professor of Renal Medicine at Manchester University NHS Foundation Trust

“Our aim is to improve the outcomes of patients on dialysis. We are continuing this study to seek more safety and performance data necessary to demonstrate H-Guard’s potential and to direct future clinical applications and testing.”

H-Guard is a potent anti-inflammatory and anti-coagulatory, second generation, complement regulator which coats the dialysis filter and tubing during the priming process. This is designed to suppress complement activation on the extracorporeal circuit’s surfaces by recruiting and enhancing the patient’s own, natural complement modulator, Factor H, whilst still allowing effective infection control.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.
AppliedVR Co-founder and President Josh Sackman, "We're committed to developing a significant body of scientific evidence that demonstrates how our RelieVRx program, which is rooted in self-regulation, cognitive behavioral therapy skills and mindfulness, engages the brain and can impact the experience of pain. While we know there can be a strong placebo effect, this feasibility study showed that only the active RelieVRx treatment created changes at a physiological and brain activity level, creating a strong foundation for future research."
Researchers and clinicians from Emory Winship Cancer Institute collaborated to test their prostate cancer population notes Prevencio.
Dilon Technologies looks to continue building evidence around its MarginProbe™ platform that already has over 12 peer-reviewed publications demonstrating reduction in re-excision rates. "We remain committed to being a leader in women's healthcare by providing technology for patients that will improve their outcomes. MarginProbe™ is beginning to become an integral component of breast surgery for more surgeons across the United States each month," stated George Makhoul, CEO of Dilon Technologies.

By using this website you agree to accept Medical Device News Magazine Privacy Policy